The Disease Interception Accelerator (DIA), part of Janssen Research & Development, LLC, is working to harness cutting-edge science to seek the most tractable interception opportunities to identify and address the root causes of select diseases. Intercepting disease will affect a paradigm shift, moving from the diagnosis and treatment of disease to one of prediction and preemption. The group is organized into venture teams, each addressing specific disease areas and seeking to develop strong collaborations and underlying capabilities that complement and propel disease interception (DI) strategies. The DIA integrates innovative science, novel therapeutics, precision diagnostics and new business models to nurture DI solutions. The DIA utilizes unique approaches to intercept disease in at-risk populations with a focus on improved individual and societal health and wellness.